Современные представления о роли простагландинов в лечении больных легочной гипертензией
Аннотация
Об авторах
О. О. МатвиенкоРоссия
Т. В. Мартынюк
Россия
И. Е. Чазова
Россия
Список литературы
1. Мартынюк Т.В., Чазова И.Е., Масенко В.П. и др. Применение простагландина Е1 в комбинации с антагонистами кальция исрадипином у больных с первичной легочной гипертензией. Кардиология, 1997; 8: 4–9.
2. Мартынюк Т.В., Масенко В.П., Чазова И.Е. и др. Эндотелиальная дисфункция у больных с легочной гипертензией. Кардиология. 1997; 10: 25–9.
3. Higenbottam T, Wheeldon D, Wells et al. Long - term tritment of primari pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1: 1046–7.
4. Barst R.T et al. Parmacologically induced pulmonary vasodilation in children and young adults with primari pulmonari hypertension. Chest 1986; 89: 497–503.
5. Barst R.J, Rubin L.J, Long W.A et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301.
6. Barst R.J, Rubin L.J, Mc Goon M.D et al. Survival in primary pulmonary hypertension with long - term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409–15.
7. Mc Laughlin V.V, Shillin A, Rich S et al. Survival in primary pulmonary hypertensio: the impact of epoprostenol therapy. Circulanion 2002; 106: 1477–82.
8. Sitbon O, Humbert M, Nunes H et al. Long - term intravenous epoprostenol infusion in privary pulmonari hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–8.
9. Badesch D.B, Tapson V.F, Mc Goon M.D at al. Continuos intravenous epoprostenol for pulmonay hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425–34.
10. Rosenzweig E.B, Kerstein D, Barst R.J. Long - term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99; 1858–65.
11. Mc Laughlin V.V, Genthner D.E, Panella M.M et al. Compassionate use of continuous prostacyclin in the management of secondary hyper tensional: a case series. Ann Intern Med 1999; 130: 740–3.
12. Kuo P.C, Johnson L.B, Plotkin J.S et al. Continues intravenous infusion of epoprostenol for the treatment of porto pulmonary hypertension. Transplantation 1997; 63: 604–6.
13. Aguilar R.V, Farber H.W. Epoprostenol therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846–50.
14. Higenbottam T, Butt A.Y, Mc Mahon A et al. Long - term intravenous prostaglandin (epoprostenol or iloprost) for teatment of severe pulmonary hypertension. Heart 1998; 80: 151–5.
15. Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124: 820–4.
16. Marius М, Hoeper M.D et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide andaerosoled iloprost in primary pulmonary hypertension. J Am Coll Cardiol 2000; 35 (1): 176–82.
17. Olschewsi H, Ghofrani H.A, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrold trail. German PPH Stady Group. Ann Intern Med 2000; 132: 435–43.
18. Olschewski R, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–9.
19. Hoeper M.M, Schwarze M, Ehlerding S et al. Long - term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866–70.
20. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218–22.
21. Ghofrani H.A, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515–22.
22. Saji T, Ozawa Y, Ishikita T et al. Short - term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244–7.
23. Galie N, Humbert M, Vachiery J.L et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, doubl - blined, placebo - controlled trial. J Am Coll Cardiol 2002; 39: 1496–502.
24. Ichida F, Vese К, Tsubata S et al. Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am J Cardiol 1997; 80: 662–4.
25. Simonneau G, Barst R.J, Galie N et al. Continuos subcutaneouse infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a doubl - blind, randomized, placebo - controlled trial. Am J Respir Crit 165: 800–4.
Рецензия
Для цитирования:
Матвиенко О.О., Мартынюк Т.В., Чазова И.Е. Современные представления о роли простагландинов в лечении больных легочной гипертензией. Системные гипертензии. 2004;(2):7-10.
Послать статью по эл. почте 